Lanadelumab

證據等級: L5

預測適應症: 10 個

Lanadelumab: From Undocumented Original Indication to C1 Inhibitor Deficiency (Hereditary Angioedema)

One-Sentence Summary

The Evidence Pack does not record a documented original indication for lanadelumab (DrugBank field empty), though supporting literature within the pack identifies it as a plasma kallikrein inhibitor developed for hereditary angioedema (HAE) prophylaxis. The TxGNN model predicts high relevance to C1 Inhibitor Deficiency, which is in fact the disease category underlying HAE — meaning this signal largely confirms an already-established indication rather than a novel repurposing opportunity. Evidence is substantial: 22 clinical trials (including one completed pivotal Phase 3 RCT) and 20 publications support this indication, but the drug is currently not marketed in Norway and safety documentation is entirely absent.

Quick Overview

Item	Content
Original Indication	Not documented in DrugBank record (field empty); literature (PMID 30267321) identifies HAE prophylaxis as the drug's known global indication
Predicted New Indication	C1 Inhibitor Deficiency
TxGNN Prediction Score	99.996%
Evidence Level	L2 (1 completed Phase 3 RCT + extensive supportive Phase 3/real-world/systematic-review evidence)
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the structured original_moa field (flagged as data gap DG002). However, literature within this Evidence Pack (PMID 30267321) describes lanadelumab as a fully human monoclonal antibody that inhibits plasma kallikrein. Mutations in the SERPING1 gene cause C1 inhibitor (C1-INH) deficiency or dysfunction, leading to uncontrolled plasma kallikrein activity and excess bradykinin production — the vasodilator believed to drive angioedema symptoms.

Importantly, "C1 inhibitor deficiency" (the predicted indication) is not a distinct new disease target relative to lanadelumab's mechanism — it is the underlying pathophysiological category of hereditary angioedema, the condition the drug's own mechanism was designed to treat. This suggests the TxGNN prediction here is best interpreted as a validation signal (the model correctly recovering a known drug-disease relationship) rather than a true off-label repurposing hypothesis. This is reinforced by the fact that lanadelumab (Takhzyro®) is already approved and marketed for HAE in the US, EU, Japan, China, and South Korea, per the clinical trial and literature evidence below — it simply has not yet obtained authorization in Norway.

Because the "original indication" field in this Evidence Pack is empty, we recommend this be treated as a data completeness issue in the source DrugBank extraction rather than genuine absence of an approved indication, and flagged for correction before this candidate proceeds further.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02586805	Phase 3	Completed	125	HELP Study — pivotal randomized, double-blind, placebo-controlled trial of lanadelumab for long-term prophylaxis against HAE attacks (Type I/II)
NCT02741596	Phase 3	Completed	212	HELP Study Extension — open-label long-term safety and efficacy follow-up
NCT04070326	Phase 3	Completed	21	SPRING Study — PK/PD and efficacy of lanadelumab in pediatric HAE patients (2–<12 years)
NCT04180163	Phase 3	Completed	12	Efficacy and safety of lanadelumab in Japanese HAE Type I/II patients
NCT05460325	Phase 3	Completed	20	Safety, PK, and efficacy of lanadelumab in Chinese HAE patients over 26 weeks
NCT04444895	Phase 3	Completed	73	Long-term safety/efficacy in non-histaminergic angioedema with normal C1-INH
NCT04687137	Phase 3	Completed	12	Japan Expanded Access Program prior to local licensure
NCT01923207	Phase 1	Completed	32	First-in-human single ascending dose safety/tolerability/PK study
NCT02093923	Phase 1	Completed	38	Multiple ascending dose safety/tolerability/PK study in HAE subjects
NCT03845400	N/A	Completed	168	EMPOWER — real-world observational study of HAE attack rates before/after lanadelumab (US/Canada)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30480729	2018	RCT	JAMA	Lanadelumab significantly reduced HAE attack rate vs placebo (HELP Study primary publication)
34287942	2022	Open-label extension	Allergy	Long-term (HELP OLE) prevention of HAE attacks confirmed in patients ≥12 years
40434599	2025	Network Meta-Analysis	Drugs in R&D	Comparative efficacy/safety of lanadelumab vs garadacimab, C1-INH, berotralstat for LTP of HAE
39508959	2024	Systematic Review	Clin Rev Allergy Immunol	Characterizes breakthrough attacks in HAE patients on long-term prophylaxis including lanadelumab
39701274	2025	Real-world observational	JACI In Practice	Multicountry INTEGRATED study confirming real-world effectiveness of lanadelumab
30267321	2018	Review	Drugs	"First Global Approval" review — MOA, development history, and regulatory status
30539362	2019	Review	BioDrugs	Review of preclinical and Phase 1 studies of lanadelumab
32187470	2020	Review	NEJM	General review of hereditary angioedema pathophysiology and treatment
37898409	2024	Review	J Allergy Clin Immunol	Burden of C1-INH-deficient HAE in the Asia-Pacific region
33602658	2021	Review	J Investig Allergol Clin Immunol	Overview of current and emerging HAE treatments including lanadelumab

Norway Market Information

No authorizations are currently registered in Norway. Lanadelumab has 0 licenses on file and is classified as 未上市 (not marketed) in this dataset, despite being approved and marketed elsewhere (US, EU, Japan, China, South Korea) as Takhzyro®.

Safety Considerations

Please refer to the package insert for safety information.

Note: This is a blocking data gap (DG001) — no TFDA/local label warnings, contraindications, or drug-drug interaction data are currently available for this candidate, and formal S1 safety evaluation cannot proceed until this is remediated.

Conclusion and Next Steps

Decision: Hold

Rationale: Efficacy evidence is strong — a completed pivotal Phase 3 RCT (HELP Study) plus extensive supportive Phase 3, real-world, and systematic-review data across multiple regulatory jurisdictions where the drug is already approved for HAE. However, the drug has zero market authorizations in Norway, and a blocking data gap prevents any formal safety review (no label warnings, contraindications, or DDI data available). The predicted indication is also effectively identical to the drug's own established use, so this should be reclassified internally as indication confirmation rather than a repurposing candidate before further action.

To proceed, the following is needed:

Local label/safety data (TFDA-equivalent warnings and contraindications) — download and parse (DG001, blocking)
Structured mechanism of action data via DrugBank API (DG002)
Correction of the empty original_indications field in the source drug record — confirm and document lanadelumab's established HAE indication
Confirmation of Norway market authorization application status, if any is planned
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.